Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of NS-079 in Healthy Participants
NCT07669571Phase 1Recruiting
- Sponsor
- NeuShen Therapeutics
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NS-079 (17 arms), sponsored by NeuShen Therapeutics. Primary endpoints: Number of Participants with Treatment-Related Adverse Events, Main pharmacokinetic parameters and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
NS-079
Beyond the preview
Go deeper on NCT07669571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07669571.